Study: Estrogen-blocking drugs work for patients with breast cancer

08/18/2011 | EurekAlert!

PET imaging with 18F-fluoroestradiol showed that estrogen-receptor-blocking drugs such as tamoxifen and fulvestrant performed better than estrogen-eliminating drugs in stopping estrogen receptor in cancer cells of patients with breast cancer metastasis to the bones, according to a study published in Clinical Cancer Research. Tamoxifen also proved to be more effective than fulvestrant in hindering estrogen, according to the study. "Our findings support the ability of FES-PET to visualize the in vivo activity of endocrine therapy," the researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
President/Chief Executive Officer
Winston-Salem, NC
Senior Vice President
Health Alliance Plan of Michigan
Southfield, MI
Director, Payer Marketing
Avalere Health
Washington, DC